ABSTRACT BACKGROUND: Although the long-term health benefits of the Mediterranean diet are well established, its efficacy for weight loss at !12 months in overweight or obese individuals is unclear. We therefore conducted a systematic review of randomized controlled trials (RCTs) to determine the effect of the Mediterranean diet on weight loss and cardiovascular risk factor levels after !12 months. METHODS: We systematically searched MEDLINE, EMBASE, and the Cochrane Library of Clinical Trials for RCTs published in English or French and with follow-up !12 months that examined the effect of the Mediterranean diet on weight loss and cardiovascular risk factor levels in overweight or obese individuals trying to lose weight. RESULTS: Five RCTs (n ¼ 998) met our inclusion criteria. Trials compared the Mediterranean diet to a lowfat diet (4 treatment arms), a low-carbohydrate diet (2 treatment arms), and the American Diabetes Association diet (1 treatment arm). The Mediterranean diet resulted in greater weight loss than the low-fat diet at !12 months (range of mean values: À4.1 to À10.1 kg vs 2.9 to À5.0 kg), but produced similar weight loss as other comparator diets (range of mean values: À4.1 to À10.1 kg vs À4.7 to À7.7 kg). Moreover, the Mediterranean diet was generally similar to comparator diets at improving other cardiovascular risk factor levels, including blood pressure and lipid levels. CONCLUSION: Our findings suggest that the Mediterranean diet results in similar weight loss and cardiovascular risk factor level reduction as comparator diets in overweight or obese individuals trying to lose weight.
In the 1950s, the landmark Seven Countries Study identified a population in the Mediterranean region that enjoyed reduced rates of cardiovascular disease and cardiovascular mortality. 1 These individuals adhered to a regional diet that consisted of a high consumption of fruits and vegetables, monounsaturated fats (primarily from olive oil), and cereals; a moderate consumption of poultry, fish, and dairy products; and little to no consumption of red meat. 2, 3 Observational studies have associated this Mediterranean diet with good overall health. 3 Although the long-term health benefits of following the Mediterranean diet are well established, its efficacy for weight loss at !12 months in overweight or obese individuals is unclear. We therefore conducted a systematic review of randomized controlled trials (RCTs) to examine the long-term effects of the Mediterranean diet on weight loss and cardiovascular risk factor levels among overweight and obese individuals trying to lose weight.
Search Strategy
We systematically searched MEDLINE (via Ovid), EMBASE (via Ovid), and the Cochrane Library of Clinical Trials from inception to January 2015 to identify RCTs that examined the effect of the Mediterranean diet on !12-month weight loss and cardiovascular risk reduction in overweight or obese individuals aged !18 years who were trying to lose weight. Our search terms consisted of medical subject headings, Emtree terms, and keywords for the Mediterranean diet (Appendices 1e3, available online). The search was restricted to RCTs published in English or in French. Moreover, we limited our MEDLINE and EMBASE searches to RCTs using a modified version of the McMaster RCT hedge. 5 We hand-searched the references of relevant RCTs, reviews, and meta-analyses retrieved by our database searches to identify additional RCTs.
Study Selection
We included RCTs that examined the efficacy of the Mediterranean diet for weight loss and cardiovascular risk factor level reduction with follow-up !12 months. Inclusion was restricted to RCTs comparing a diet that was described explicitly as "Mediterranean," "Mediterranean-Style," or "Mediterranean-inspired" to any active comparator diet, including but not limited to low-fat diets, low-carbohydrate diets, calorie-restricted diets, and diets that are part of the usual care for certain medical conditions. Trials with an exercise prescription or nutritional counseling in intervention or comparator arms were eligible for inclusion provided that !2 arms of the trial received the same exercise prescription or nutritional counseling. This was done to isolate the effect of the Mediterranean diet.
We excluded trials conducted in participants with malignancies or posttransplantation, as well as weight maintenance trials. We also excluded trials with a crossover design, unless the initial phase of the trial preceding the crossover was randomized, controlled, and lasted !12 months; the initial phase of such trials was included. Finally, nonrandomized trials, uncontrolled trials, and those that did not provide counseling or exercise interventions equally to !2 arms of the trial were designated as having an inappropriate control group and were thus excluded.
Data Extraction and Synthesis
Data were extracted by 2 independent reviewers, with disagreements resolved by consensus. Extracted data included data on study characteristics, study population, demographic and clinical characteristics, intervention characteristics, and use of any co-interventions such as exercise or counseling.
All outcome data were extracted at 12 months, as well as at 6 months and in 6-month increments beyond 12 months, if available, until maximum follow-up.
Our primary endpoint was sustained weight loss, reported as mean weight change in kilograms or as a mean percentage change, at !12 months or longest follow-up.
Secondary endpoints included mean change in body mass index (BMI), body fat, waist circumference, waist-hip ratio, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure, fasting glucose, fasting insulin, homeostatic model assessment, and glycated hemoglobin (HbA1c) levels. The quality of included trials was assessed using the Cochrane Collaboration's tool for assessing risk of bias in RCTs. 6 Quality assessment was conducted by 2 independent reviewers, with disagreements resolved by consensus. Given the amount of heterogeneity that was present in the designs, populations, and comparators among the included RCTs, we were unable to statistically pool data across trials.
RESULTS

Search Results
Our search yielded 2432 potentially relevant publications (Appendix 4, available online). Following the removal of duplicates, 1069 publications underwent title and abstract screening. Of these, 78 were retrieved for full-text screening, and 5 were included in the systematic review.
Study Characteristics
The 5 included RCTs (n ¼ 998) randomized participants to a Mediterranean diet (6 treatment arms; n ¼ 492) or a lowfat diet (4 treatment arms; n ¼ 312), a low-carbohydrate diet (1 treatment arm; n ¼ 109), or the American Diabetes Association diet (1 treatment arm; n ¼ 85) ( Table 1) . Followup ranged from 12 to 48 months, with 2 studies also reporting 6-month outcomes. 7, 8 The 5 RCTs possessed varying degrees of bias, according to the Cochrane Collaboration's risk of bias assessment tool for RCTs. Most trials had a low or unclear risk of bias for sequence generation (5 trials), allocation concealment (4 trials), and blinding (4 trials). However, 1 RCT 7 was deemed to have a high risk of selective outcome reporting. Moreover, 2 RCTs 9,10 were found to be high risk in 3 and 4 domains, respectively. In particular, these RCTs were at high risk of bias for incomplete outcome data and selective outcome reporting due to a high rate of loss to follow-up and
CLINICAL SIGNIFICANCE
The long-term efficacy of the Mediterranean diet for weight loss in overweight or obese individuals was previously unclear. The Mediterranean diet is superior to low-fat diets for long-term weight loss. Given the popularity of the Mediterranean diet and the importance of weight management in light of the current obesity epidemic, this review provides essential information for public health improvement. †This represents the number of participants included in the analysis of outcomes at maximum follow-up. ‡All 322 participants were included in the primary analyses, and the most recent values for weight and blood pressure were used. §Risk factors and nutrient intake was compared by using a test based on the values at the end of follow-up and a t-test based on differences from baseline. Due to a low rate of loss to follow-up, a complete case analysis was used for secondary outcomes.
kOnly participants who attended follow-up were analyzed. ¶The timeframe by which a diagnosis of type 2 diabetes mellitus was considered "new" was not specified.
incomplete outcome reporting, respectively (Appendix 5, available online).
Participant Characteristics
The average age of participants ranged from 44 to 67 years ( Table 1) . On average, participants were borderline obese or obese, with mean BMIs ranging from 29.7 to 33.5 kg/m 2 and mean body weights ranging from 85.9 to 91.4 kg. Moreover, only 1 RCT assessed the effects of the Mediterranean diet in overweight but otherwise healthy individuals, of whom 90.1% were women. 10 The remaining 4 RCTs included participants with elevated cardiovascular disease risk, including participants with type 2 diabetes (3 trials), coronary heart disease (1 trial), or a recent myocardial infarction (1 trial). The 2 RCTs conducted in patients with cardiovascular disease consisted mainly of male participants (74%-86%). 7, 8 The distribution of male and female participants was balanced in 2 RCTs.
9,11
Weight Loss and Change in Other Anthropometric Measures
In general, the Mediterranean diet was modestly efficacious at reducing body weight (range of mean changes: À3.8 to À10.1 kg) at !12 months ( Table 2) . In 3 RCTs, the Mediterranean diet was significantly more efficacious for weight loss than a low-fat diet at !12 months. 8, 10, 11 However, the Mediterranean diet produced similar weight loss as other comparator diets at !12 months (range of mean changes: À4.7 to À7.7 kg). 8, 9 The effect of the Mediterranean diet on BMI was similar to that for weight reduction ( Table 2) . At !12 months, the Mediterranean diet was more efficacious than a low-fat diet at reducing BMI (range of mean changes: À1.0 to À3.3 kg/ m 2 vs 1.4 to À1.8 kg/m 2 ), but similar to all other comparator diets (range of mean changes: À1.5 to À2.8 kg/m 2 ). Similar trends were observed when examining waist circumference ( Table 2) .
Other Cardiovascular Risk Factor Levels
The Mediterranean diet produced similar effects on measures of glycemic control as other diets but resulted in greater improvements in patients with type 2 diabetes ( Table 3 and Appendix 6, available online). In particular, participants with type 2 diabetes demonstrated significant improvement from baseline in levels of fasting glucose, serum insulin, and the homeostatic model assessment with the Mediterranean diet. [7] [8] [9] 11 The Mediterranean diet resulted in greater reductions in fasting glucose levels in patients with type 2 diabetes than comparator diets at !12 months (range of mean changes: À0.89 to À4.30 mmol/L vs 0.67 to À3.10 mmol/L) and greater improvements in HbA1c levels.
Changes in lipid levels were generally similar with the Mediterranean diet as with comparator diets (Table 4) . More specifically, the Mediterranean diet was similar to other diets with respect to changes in low-density and high-density lipoprotein cholesterol levels. However, the Mediterranean diet resulted in greater reductions in triglyceride levels than comparator diets at !12 months (range of mean changes: À0.25 to À1.50 mmol/L vs À0.03 to À0.70 mmol/L).
Only 3 RCTs reported changes in blood pressure, with available data suggesting that the Mediterranean diet has similar effects on systolic and diastolic blood pressure levels as comparator diets (Table 5) . 7, 8, 11 Only one trial demonstrated a significantly greater reduction in systolic and diastolic blood pressure at 12 months with the Mediterranean diet compared with a low-fat diet. 11 In the second trial, 7 which consisted of participants with normal blood pressure at baseline, no difference between the Mediterranean diet and a low-fat diet was detected, with blood pressure increasing modestly in both groups during follow-up. In the third trial, 8 no difference was observed between groups, though blood pressure decreased slightly in the 3 groups during follow-up.
DISCUSSION
Our systematic review was designed to examine the longterm (!12 months) effect of the Mediterranean diet on weight loss and cardiovascular risk factor levels among overweight and obese individuals trying to lose weight. We found that the Mediterranean diet is more efficacious for !12-month weight loss compared with low-fat diets, but not compared with other comparator diets. The Mediterranean diet also resulted in greater improvements in triglyceride levels but produced similar changes in other lipid levels and blood pressure. Furthermore, we found that it improved measures of glycemic control among patients with type 2 diabetes, but not in normoglycemic individuals. Taken together, our findings suggest that the Mediterranean diet is efficacious for weight loss and cardiovascular risk level reduction in overweight or obese individuals, but not more so than other diets.
The findings from this systematic review add to the literature suggesting that there is no ideal diet for achieving sustained weight loss in overweight or obese individuals. This is consistent with the findings of our previous systematic review 12 of popular commercial diets, in which we found that Atkins, Weight Watchers, and Zone all produced similar weight loss at !12 months. Importantly, the weight loss at !12 months with the Mediterranean diet in the present systematic review is consistent with that observed with these commercial diets in the previous one. The similar weight loss achieved with these diets reduces the concern raised by the creators of some of these commercial diets [13] [14] [15] about the elevated consumption of carbohydrates associated with the Mediterranean diet. 2 The similar weight loss achieved across diets suggests that there is no optimal macronutrient composition for achieving sustained weight loss.
Rather, it has been suggested that a "3-stepped intensification of care approach" is more likely to yield clinically Values are reported as: mean AE standard deviation, unless otherwise specified. ADA ¼ American Diabetes Association; NR ¼ not reported. *Studies are listed in descending order of number of participants included in the analyses of each trial. †n is the number of participants analyzed for each arm of the trial at a specific point of follow-up (shown in Table 1 ). ‡Mean change was calculated as difference of means from baseline to follow-up from data of the publication. §P <.05 vs low-fat diet. kReported in the publication without discernable standard deviation.
significant weight loss. 16 The first step is evidence-based lifestyle modification through diet, behavioral therapy, and physical activity. 16 Combining diet with physical activity has been found to increase weight loss compared with each of these interventions used alone, [17] [18] [19] with physical activity unlikely to yield clinically significant weight loss unless it comprises a high level of aerobic exercise or is used in conjunction with a calorie-restricted diet. 17 The second step is the concurrent use of weight loss pharmacotherapies. 16 The third step is bariatric surgery for individuals for whom interventions from the prior steps have failed and who suffer from severe obesity or moderate obesity with comorbidities. 16 The Mediterranean diet has been the focus of many epidemiological studies, but the diet itself originated inauspiciously during the early to mid-20 th century. The dietary pattern consisting of the elevated consumption of fruits and vegetables, legumes, cereals, and olive oil was followed, for the most part, in poor, rural regions of the Mediterranean.
3 Individuals in these communities enjoyed numerous health benefits, including reduced rates of cardiovascular disease, which were first described by the Seven Countries Study. 20 More recently, cohort studies have underscored the Mediterranean diet's impact on overall health, suggesting that adherence to the Mediterranean diet is associated with up to 50% reduced risk of developing the metabolic syndrome, 21 an increase in levels of biomarkers associated with healthy aging, 22 and a reduced risk of mortality over 20 years. 23 The Prevencíon con Dieta Mediterránea (PREDIMED) RCT further highlighted the potential of the Mediterranean diet as an intervention for the primary prevention of cardiovascular disease. A total of 7447 individuals at high risk of developing cardiovascular disease were randomized to the Mediterranean diet supplemented with olive oil, the Mediterranean diet supplemented with nuts, or a low-fat diet, and followed for a median of 4.8 years. Compared with the low-fat diet, the Mediterranean diet was associated with an approximate 30% reduction in the primary, composite endpoint of myocardial infarction, stroke, or cardiovascular death, with similar benefits observed in both Mediterranean diet arms. 24, 25 Other cardiovascular health benefits observed with the Mediterranean diet included: decreases in incident type 2 diabetes, peripheral artery disease, and atrial fibrillation rates; metabolic syndrome reversion; decreases in blood pressure, hypertension risk, and carotid atherosclerosis. 25 Many interactions were observed between Mediterranean diet and genetic determinants of intermediate and cardiovascular disease phenotypes. Often, the extent of these cardiovascular health benefits was correlated with the extent of adherence. 25 There are several possible explanations for the differences in results between the aforementioned studies and our systematic review. In order to obtain the most rigorous form of evidence possible, we restricted inclusion to RCTs that 10 did not report glycemic control measures and was therefore not included in this Table. †n is the number of participants analyzed for each arm of the trial at a specific point of follow-up (shown in Table 1 ). ‡Randomized controlled trials by Shai et al 8 and Tuttle et al 7 reported glycemic control measures among diabetic and nondiabetic participants. Please see Appendix 6.
§P <.05 for difference between groups. kMean change was calculated as difference of means from baseline to follow-up from data of the publication. ¶P <.05 vs ADA diet. 10 did not report changes in lipid profiles throughout follow-up and was therefore not included in this Table. †n is the number of participants analyzed for each arm of the trial at a specific point of follow-up (shown in Table 1 ). ‡Mean change was calculated as difference of means from baseline to follow-up from data of the publication. §P <.05 vs low-fat diet. kP <.05 vs ADA diet. ¶P <.05 vs Mediterranean diet. **Reported with no discernable standard deviation.
compared the Mediterranean diet to active comparator diets. Much of the evidence for the Mediterranean diet's health benefits comes from observational studies, 21, 26 which often lack an appropriate comparator, and without the benefits of randomization, are prone to confounding and selection biases. In addition, several of these epidemiologic studies 23, 26, 27 focused on the overall health benefits of the Mediterranean diet without focusing on its use among overweight and obese individuals trying to lose weight. Finally, we excluded short-term trials, which are more likely to show a favorable benefit with the Mediterranean diet, focusing on RCTs with longer-term follow-up data, as longterm weight loss represents a more important predictor of cardiovascular disease events. 28 Although previous knowledge syntheses have examined the Mediterranean diet for weight loss, many had several important methodological limitations. These include recent meta-analyses, 29, 30 which pooled data across trials despite the presence of important heterogeneity in study design, durations of follow-up, and comparators. Moreover, previous reviews and meta-analyses [29] [30] [31] [32] included RCTs that involved preferential nutritional counseling in Mediterranean diet treatment arms, which has been previously shown to increase 12-month weight loss. 33 The inclusion of such trials may partially explain the positive findings of these previous reviews and meta-analyses. [29] [30] [31] [32] With inclusion restricted to trials with appropriate comparators and synthesis focused on the qualitative assessment of the available data in light of the substantial heterogeneity of included trials, the present systematic review has thus overcome the limitations of many previous studies in this area.
Limitations
Our systematic review has several potential limitations. First, it was designed to focus on high-quality evidence from long-term RCTs. Consequently, only 5 RCTs were included, and these trials included a total of <1000 patients. With heterogeneity in design, population, and comparator, we were unable to statistically pool data across trials. However, this finding highlights the dearth of rigorous trials in this area. Second, with 89.9% of included participants having established cardiovascular disease or type 2 diabetes, the generalizability of our results to the general population of overweight or obese individuals trying to lose weight is unclear. Nonetheless, the high proportion of such individuals allowed for the assessment of the Mediterranean diet in individuals with obesity-associated comorbidities. Finally, our review was restricted to RCTs that explicitly mentioned the Mediterranean diet as a dietary intervention. Mediterranean-style diet (n ¼ 47) Values are reported as: mean AE standard deviation, unless otherwise specified. *Studies are listed in descending order of number of participants included in the analyses of each trial. Studies that did not report blood pressure changes throughout follow-up were not included in this Table. †n is the number of participants analyzed for each arm of the trial at a specific point of follow-up (shown in Table 1 ). ‡P <.05 vs low-fat diet.
This may have resulted in the exclusion of some RCTs that investigated diets with the alimentary and macronutrient composition of the Mediterranean diet without describing the intervention as such. However, this ensured that included RCTs studied the diet of interest.
CONCLUSION
Our systematic review was designed to investigate the effect of the Mediterranean diet on weight loss and cardiovascular risk factor levels among overweight or obese individuals trying to lose weight. Our results suggest that the Mediterranean diet results in greater weight loss than a low-fat diet, but similar weight loss as other comparator diets. The Mediterranean diet may also improve triglyceride levels as well as produce similar changes in blood pressure and other lipids as comparator diets. Although following the Mediterranean diet may result in some weight loss, and it likely has other health benefits, it does not appear to be superior to other diets when followed by overweight or obese individuals trying to lose weight.
